Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesBariatric & Obesity ManagementCVS Caremark Qsymia Prior Auth Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 794-C

    Initial Prior Authorization with Quantity Limit Qsymia Weight Loss Management

    Customize your policy alerts

    Sign up for cvs_caremark Policy 794-C alerts

    Get alerted when Policy 794-C changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs initial and continuation prior authorization, dose escalation, and quantity limits for Qsymia (phentermine/topiramate extended-release) used with diet and physical activity for weight reduction or long-term maintenance in adults and patients aged 12 years and older who meet specified eligibility criteria.

    Policy Summary
    PayerCVS Caremark
    PolicyInitial Prior Authorization with Quantity Limit Qsymia Weight Loss Management
    Policy CodePolicy 794-C
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization for initial therapy, dose escalation to Qsymia 11.25 mg/69 mg, and continuation therapy, while observing applicable quantity limits.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12+ yearsMinimum patient age for covered use
    6 monthsRequired weight-management program before drug therapy
    3.75/23–15/92 mgQsymia strengths subject to quantity limits
    30/25 days

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    One-month quantity limit
    90/75 daysThree-month quantity limit
    4 or 12 monthsApproval duration

    Qsymia Coverage Criteria

    Initial Therapy

    Authorization may be granted when ALL of the following are met.

    Initial therapy requirements

    • The requested drug will be used with a reduced-calorie diet AND increased physical activity to reduce excess body weight or maintain weight reduction long term.
    • The patient has participated in a comprehensive weight-management program that encourages behavioral modification, a reduced-calorie diet, and increased physical activity with continuing follow-up for at least 6 months before using drug therapy.At least 6 months before drug therapy
    • ONE age-based eligibility pathway

      • Adult eligibility

        • Adult obesity: The patient is 18 years of age or older and has a baseline body mass index (BMI) greater than or equal to 30 kg/m².BMI >= 30 kg/m²

          If transitioning from another drug therapy for weight loss, use the baseline BMI at the start of any drug therapy.

        • Adult overweight with comorbidity

          • The patient is 18 years of age or older and has a baseline BMI greater than or equal to 27 kg/m².BMI >= 27 kg/m²

            If transitioning from another drug therapy for weight loss, use the baseline BMI at the start of any drug therapy.

          • The patient has at least ONE weight-related comorbid condition, such as hypertension, type 2 diabetes mellitus, or dyslipidemia.

            If transitioning from another drug therapy for weight loss, consider the weight-related comorbid condition(s) present at the start of drug therapy.

      • Pediatric eligibility: The patient is 12 to 17 years of age and has a baseline BMI in the 95th percentile or greater, standardized for age and sex.BMI >= 95th percentile

        If transitioning from another drug therapy for weight loss, use the baseline BMI at the start of any drug therapy.

    The safety and effectiveness of Qsymia in combination with other products intended for weight loss—including prescription drugs, over-the-counter drugs, and herbal preparations—have not been established.

    Eligibility and Response Thresholds

    Adult obesity baseline BMI
    Eligible populationAdults 18 years of age or older
    Baseline BMI thresholdGreater than or equal to 30 kg/m²
    Baseline measurementWhen transitioning from another weight-loss drug, use the BMI at the start of any drug therapy
    Adult overweight baseline BMI
    Eligible populationAdults 18 years of age or older
    Baseline BMI thresholdGreater than or equal to 27 kg/m²
    Additional requirementAt least one weight-related comorbid condition, such as hypertension, type 2 diabetes mellitus, or dyslipidemia

    Authorization, Documentation, and Denial Rules

    Prior Authorization

    Prior Authorization Required for Initial, Escalation, and Continuation Therapy

    Obtain prior authorization for initial therapy, dose escalation, and continuation of Qsymia. Initial and escalation approval is limited to 4 months; continuation approval is limited to 12 months. The requested use must be with a reduced-calorie diet and increased physical activity, and escalation to 11.25 mg/69 mg must follow the recommended dose-escalation schedule.

    • Initial therapy and dose escalation with 11.25 mg/69 mg: 4-month duration of approval.
    • Continuation therapy: 12-month duration of approval.
    • Document the applicable dose, treatment phase, and recommended escalation schedule for requests involving Qsymia 11.25 mg/69 mg.
    Documentation Required

    Document Baseline BMI

    Document the patient's baseline BMI for approval. For adults transitioning from another weight-loss drug, use the BMI at the start of any drug therapy when determining eligibility.

    Qsymia Use in Weight Management

    Qsymia is indicated for use with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term. The policy applies to adults and adolescents aged 12 years and older with obesity, and to adults with overweight who have at least one weight-related comorbid condition.

    Policy Terms

    Qsymia
    ProductQsymia
    Active ingredientsPhentermine and topiramate
    FormulationExtended-release
    Policy Summary
    PayerCVS Caremark
    PolicyInitial Prior Authorization with Quantity Limit Qsymia Weight Loss Management
    Policy CodePolicy 794-C
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization for initial therapy, dose escalation to Qsymia 11.25 mg/69 mg, and continuation therapy, while observing applicable quantity limits.
    SourceLink
    On This Page
    Qsymia Coverage CriteriaEligibility and Response ThresholdsAuthorization, Documentation, and Denial RulesQsymia Use in Weight ManagementPolicy Terms
    Pediatric baseline BMI
    Eligible populationPatients 12 to 17 years of age
    Baseline BMI thresholdAt or above the 95th percentile
    StandardizationStandardized for age and sex
    Adult response after 15 mg/92 mg
    Therapy strengthQsymia 15 mg/92 mg
    Required responseAt least 5% loss of baseline body weight, or maintenance of the initial 5% weight loss
    Assessment periodAfter at least 12 weeks of therapy
    Adult response after 7.5 mg/46 mg
    Therapy strengthQsymia 7.5 mg/46 mg
    Required responseAt least 3% loss of baseline body weight, or maintenance of the initial 3% weight loss
    Assessment periodAfter at least 12 weeks of therapy
    Pediatric response after 15 mg/92 mg
    Therapy strengthQsymia 15 mg/92 mg
    Required responseAt least 5% reduction of baseline BMI, or maintenance of the initial 5% BMI reduction
    Assessment periodAfter at least 12 weeks of therapy
    Pediatric response after 7.5 mg/46 mg
    Therapy strengthQsymia 7.5 mg/46 mg
    Required responseAt least 3% reduction of baseline BMI, or maintenance of the initial 3% BMI reduction
    Assessment periodAfter at least 12 weeks of therapy
    • Adults: baseline BMI ≥30 kg/m², or baseline BMI ≥27 kg/m² with at least one qualifying weight-related comorbidity.
    • Patients aged 12 to 17 years: baseline BMI must be at or above the 95th percentile, standardized for age and sex.
    • Documentation of the applicable baseline BMI is required for approval.
    Documentation Required

    Document Weight-Related Comorbidity

    For adults with a baseline BMI of at least 27 kg/m² but less than 30 kg/m², document at least one qualifying weight-related comorbid condition. If transitioning from another weight-loss drug, document the comorbidity status at the start of any drug therapy.

    • Examples include hypertension, type 2 diabetes mellitus, and dyslipidemia.
    • Documentation of the qualifying comorbidity is required for approval.
    Documentation Required

    Document Pediatric BMI Eligibility

    For patients aged 12 to 17 years, document a baseline BMI at or above the 95th percentile, standardized for age and sex. If the patient is transitioning from another weight-loss drug, use the BMI at the start of any drug therapy.

    • The pediatric BMI percentile requirement is ≥95th percentile.
    • Documentation of the baseline BMI percentile is required for approval.
    Documentation Required

    Document Continuation Response

    For continuation approval, document the required response after at least 12 weeks of therapy and document maintenance of the response when applicable. Adult response is measured by body weight; pediatric response is measured by BMI.

    • Adults after 12 weeks of 15 mg/92 mg: at least 5% loss of baseline body weight or maintenance of the initial 5% loss.
    • Adults after 12 weeks of 7.5 mg/46 mg: at least 3% loss of baseline body weight or maintenance of the initial 3% loss.
    • Patients aged 12 to 17 years after 12 weeks of 15 mg/92 mg: at least 5% reduction in baseline BMI or maintenance of the initial 5% reduction.
    • Patients aged 12 to 17 years after 12 weeks of 7.5 mg/46 mg: at least 3% reduction in baseline BMI or maintenance of the initial 3% reduction.
    • Document dose escalation to 11.25 mg/69 mg and adherence to the recommended escalation schedule when applicable.
    Denial Risk

    Initial Criteria Not Met: Coverage May Be Denied

    Coverage may be denied when the initial-therapy requirements are not met or cannot be documented. Before submitting the request, verify the required lifestyle program, age-specific eligibility, and supporting documentation.

    • The patient must have participated in a comprehensive weight-management program with behavioral modification, a reduced-calorie diet, increased physical activity, and continuing follow-up for at least 6 months before drug therapy.
    • Adults must meet the applicable BMI threshold; adults with BMI ≥27 kg/m² must also have at least one qualifying weight-related comorbidity.
    • Patients aged 12 to 17 years must meet the 95th-percentile BMI requirement standardized for age and sex.
    • Missing baseline BMI, BMI percentile, comorbidity, or other required eligibility documentation may result in denial.
    Denial Risk

    Continuation Criteria Not Met: Coverage May Be Denied

    Continuation coverage may be denied when the patient does not demonstrate or maintain the required response after at least 12 weeks, or when required dose escalation is not documented and performed according to the recommended schedule.

    • Adult response thresholds are 5% after 15 mg/92 mg or 3% after 7.5 mg/46 mg; the patient may instead document maintenance of the applicable initial response.
    • Pediatric response thresholds are a 5% or 3% reduction in baseline BMI, as applicable; the patient may instead document maintenance of the applicable initial BMI reduction.
    • Document the required response or maintenance and, when applicable, escalation to 11.25 mg/69 mg under the recommended schedule.
    Denial Risk

    Quantity Limit Exceeded

    Claims exceeding the Qsymia quantity limits may be denied. The limits apply to each listed strength, including 3.75 mg/23 mg, 7.5 mg/46 mg, 11.25 mg/69 mg, and 15 mg/92 mg.

    • 1-month limit: 30 capsules per 25 days.
    • 3-month limit: 90 capsules per 75 days.
    • The 25-day and 75-day periods allow time for refill processing within 30-day and 90-day fill periods.
    Denial Risk

    Do Not Combine With Other Weight-Loss Products

    Do not use Qsymia concurrently with other products intended for weight loss. The safety and effectiveness of combination use have not been established.

    • Concurrent use with prescription weight-loss drugs is not supported.
    • Concurrent use with over-the-counter weight-loss products is not supported.
    • Concurrent use with herbal weight-loss preparations is not supported.